一例NCAM1阳性狼疮性肾炎患者，其NCAM1抗体滴度对利妥昔单抗有反应

A Case of NCAM1-Positive Lupus Nephritis with NCAM1 Antibody Titers Responsive to Rituximab.

作者信息

Wang Yifeng, Chen Ruiying, Han Min, Liu Shaojun, Xie Qionghong, Hao ChuanMing

机构信息

Department of Nephrology, Huashan Hospital, Fudan University, Shanghai, China,

Department of Nephrology, Huashan Hospital, Fudan University, Shanghai, China.

出版信息

Nephron. 2024;148(5):312-318. doi: 10.1159/000534037. Epub 2023 Sep 29.

DOI:10.1159/000534037

PMID:37778328

Abstract

Neural cell adhesion molecule 1 (NCAM1) is a recently identified new antigen of membranous nephropathy (MN) mostly secondary to systemic lupus erythematosus with a low positive rate of 6.6%, and its corresponding antibody was detected in patients' sera. Here, we reported a case of NCAM1-positive lupus nephritis (class V+III) developed from MN. The patient was refractory to multiple immunosuppressive regimens but achieved remission after the application of rituximab as an add-on therapy and showed a reduction of anti-NCAM1 antibody and proteinuria.

摘要

神经细胞黏附分子1（NCAM1）是最近发现的膜性肾病（MN）的一种新抗原，大多继发于系统性红斑狼疮，阳性率较低，为6.6%，且在患者血清中检测到了其相应抗体。在此，我们报告了1例由MN发展而来的NCAM1阳性狼疮性肾炎（V+III型）病例。该患者对多种免疫抑制方案均耐药，但在应用利妥昔单抗作为附加治疗后病情缓解，抗NCAM1抗体和蛋白尿均减少。